Loading clinical trials...
Loading clinical trials...
Double-Blind, Randomized, Placebo-Controlled, Multi-Center Trial to Assess Safety, Tolerability, and PK of the Anti-Orthopoxvirus Compound ST-246 When Administered as a Single Daily Oral Dose for 14 Days in Volunteers in the Fed State
Conditions
Interventions
ST-246 400 mg
ST-246 600 mg
+1 more
Locations
3
United States
Apex Research Institute
Santa Ana, California, United States
Orlando Clinical Research Center
Orlando, Florida, United States
Hawaii Clinical Research Center
Honolulu, Hawaii, United States
Start Date
June 1, 2009
Primary Completion Date
January 1, 2010
Completion Date
January 1, 2010
Last Updated
September 21, 2010
Lead Sponsor
SIGA Technologies
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions